Author

Cristina I. Caescu

Columbia University Irving Medical CenterORCID 0000-0003-4200-2779Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Systems Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Research Focus:drug response / drug discovery· 2 Organism:human· 2 Approach:statistical model· 2 Approach:machine learning (classical)· 1 Assay:scRNA-seq· 1

Frequent Co-Authors

Adina GrunniD· 2 shared Andrea CalifanoiD· 2 shared Charles KaraniD· 2 shared Gary K. SchwartziD· 2 shared Hanina H. HibshooshiD· 2 shared Mahalaxmi AburiiD· 2 shared Mariano J. AlvareziD· 2 shared Prabhjot Singh MundiiD· 2 shared

Activity by Year

2023-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Adina GrunnORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologybioRxivPreprintOct 12, 2025

Systematic elucidation and pharmacologic targeting of non-oncogene dependencies in imatinib-resistant gastrointestinal stromal tumor

Prabhjot Singh Mundi, Adina Grunn, Arsenije Kojadinovic…·Andrea Califano

This study identifies non-oncogene dependencies in imatinib-resistant GIST using network-based methods and validates six drugs that reverse MR activity in preclinical models.

DOI 10.1101/2025.10.12.681609

humanbulk RNA-seq

𝕏 PostBluesky

Systems BiologyCancer DiscoveryPeer-reviewedApr 16, 2023

Pre-clinical validation of an RNA-based precision oncology platform for patient-therapy alignment in a diverse set of human malignancies resistant to standard treatments

Prabhjot Singh Mundi, Filemon S. Dela Cruz, Adina Grunn…·Andrea Califano

The paper validates an RNA-based platform for predicting drug sensitivity in treatment-resistant cancers using patient-derived xenograft models and multi-protein therapies.

51 citationstop 2%

humanbulk RNA-seq

𝕏 PostBluesky